These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28143634)

  • 1. The Treatment of Hepatitis C- An Introduction to the Use of New Medicines.
    Wörmann B
    Dtsch Arztebl Int; 2017 Jan; 114(1-02):9-10. PubMed ID: 28143634
    [No Abstract]   [Full Text] [Related]  

  • 2. The new hepatitis C era: the guidelines are now available, reimbursement not yet..
    Hullegie SJ; Rijnders BJ
    Neth J Med; 2014 Oct; 72(8):386-7. PubMed ID: 25387550
    [No Abstract]   [Full Text] [Related]  

  • 3. Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study.
    Geenen JW; Boersma C; Klungel OH; Hövels AM
    Eur J Health Econ; 2019 Aug; 20(6):857-867. PubMed ID: 30953216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prescription of new HCV-drugs - what has to be considered judicially].
    Mauss S
    Z Gastroenterol; 2015 Jan; 53(1):43-5. PubMed ID: 25594707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public procurement of hepatitis C medicines in Brazil from 2005 to 2015.
    Chaves GC; Castro CGSO; Oliveira MA
    Cien Saude Colet; 2017 Aug; 22(8):2527-2538. PubMed ID: 28793069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus infection: accessing drug treatment.
    Smyth D; Webster D
    CMAJ; 2015 Oct; 187(15):1113-1114. PubMed ID: 26303249
    [No Abstract]   [Full Text] [Related]  

  • 7. The science, economics, and effectiveness of combination therapy for hepatitis C.
    Read B
    Gut; 2001 Mar; 48(3):441. PubMed ID: 11256364
    [No Abstract]   [Full Text] [Related]  

  • 8. [Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
    Reiser M; Haverkamp A; Dintsios M; Mölleken C; Krauth C; Pieper W; Schmiegel W
    Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1743-7. PubMed ID: 17713882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. US health insurers say Gilead hepatitis C drug too costly.
    Clin Infect Dis; 2014 Jul; 59(2):i-ii. PubMed ID: 25105185
    [No Abstract]   [Full Text] [Related]  

  • 10. [Because fee settlement means are not widely known. Deficits in hepatitis C therapy].
    MMW Fortschr Med; 2003 May; 145(19):55. PubMed ID: 12813986
    [No Abstract]   [Full Text] [Related]  

  • 11. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?
    van de Vooren K; Curto A; Garattini L
    Eur J Health Econ; 2015 May; 16(4):341-5. PubMed ID: 25407841
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis C: how has France limited the expenses related to new treatments?
    Mouterde AL; Bocquet F; Fusier I; Paubel P
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):655-657. PubMed ID: 27732130
    [No Abstract]   [Full Text] [Related]  

  • 13. State Efforts to Lower Health Care Prices Paid by Private Insurers.
    Sen AP; Willink A; Anderson GF
    JAMA; 2019 Jul; 322(3):201-202. PubMed ID: 31194215
    [No Abstract]   [Full Text] [Related]  

  • 14. Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.
    Brunetto MR; De Luca A; Messori A; Zignego AL
    BMJ; 2015 Jun; 350():h3363. PubMed ID: 26108546
    [No Abstract]   [Full Text] [Related]  

  • 15. Dare to refuse the exorbitant price of Sovaldi!
    Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: National health spending in 2011: overall growth remains low, but some payers and services show signs of acceleration.
    Penson DF
    J Urol; 2013 Sep; 190(3):1004-5. PubMed ID: 23931227
    [No Abstract]   [Full Text] [Related]  

  • 17. Market watch: The industry's biggest drug launches.
    Urquhart L
    Nat Rev Drug Discov; 2018 Nov; 17(12):855. PubMed ID: 30482955
    [No Abstract]   [Full Text] [Related]  

  • 18. Tackling the hepatitis C cost problem: A test case for tomorrow's cures.
    Simon RE; Pearson SD; Hur C; Chung RT
    Hepatology; 2015 Nov; 62(5):1334-6. PubMed ID: 26359645
    [No Abstract]   [Full Text] [Related]  

  • 19. The economics of hepatitis C virus.
    Shah BB; Wong JB
    Clin Liver Dis; 2006 Nov; 10(4):717-34. PubMed ID: 17164114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The future of private health insurance].
    Ostendorf GM
    Versicherungsmedizin; 2014 Mar; 66(1):40. PubMed ID: 24683899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.